Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $41,536.35 in Stock

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) CFO Stephen Furlong sold 10,845 shares of the business's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $3.83, for a total value of $41,536.35. Following the completion of the transaction, the chief financial officer now owns 471,727 shares in the company, valued at $1,806,714.41. This trade represents a 2.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Stephen Furlong also recently made the following trade(s):

• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Stock Performance

Neuronetics stock traded up $0.35 during trading hours on Tuesday, hitting $4.71. The stock had a trading volume of 1,482,011 shares, compared to its average volume of 1,628,062. The company has a 50-day moving average of $2.27 and a two-hundred day moving average of $1.43. The company has a quick ratio of 2.87, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The company has a market cap of $142.80 million, a PE ratio of -3.83 and a beta of 2.17. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.07.

Institutional Investors Weigh In On Neuronetics

A number of large investors have recently bought and sold shares of STIM. Balyasny Asset Management L.P. grew its position in Neuronetics by 29.5% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company's stock worth $2,386,000 after acquiring an additional 337,539 shares during the last quarter. HighTower Advisors LLC grew its position in Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company's stock worth $187,000 after acquiring an additional 87,816 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Neuronetics during the 3rd quarter worth approximately $53,000. JPMorgan Chase & Co. grew its position in Neuronetics by 10,954.1% during the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock worth $88,000 after acquiring an additional 54,442 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after buying an additional 30,837 shares in the last quarter. 53.59% of the stock is currently owned by institutional investors.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.